CXCL9 Molekülinformation
Molecule Name
C-X-C motif chemokine 9
Molekülalias
CMK, Humig, MIG, SCYB9, crg-10
Drug Development Progress
Anzahl der klinischen Arzneimittel1
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
C-X-C motif chemokine 9，Gamma-interferon-induced monokine，Monokine induced by interferon-gamma (HuMIG; MIG)，Small-inducible cytokine B9，SCYB9，Crg-10，Humig，CMK，MIG，Monokine Induced By Gamma Interferon，Monokine Induced By Interferon-Gamma，Gamma-Interferon-Induced Monokine，Chemokine (C-X-C Motif) Ligand 9，Small-Inducible Cytokine B9，C-X-C Motif Chemokine 9，HuMIG
Molekülhintergrund
CXCL9 is a small cytokine belonging to the CXC chemokine family that is also known as monokine induced by gamma interferon (MIG). CXCL9 is a chemokine that plays a role in immune responses, it can induce chemotaxis, promote differentiation and proliferation of leukocytes, and cause tissue extravasation. CXCL9 regulates immune cell migration, differentiation and activation by binding to CXCR3 receptor, such as CTLs, NK cells, NKT cells and macrophages. CXCL9 also participates in Th1 polarization and IFN-γ response.
Produktanfrage
Asset Licensing Opportunity
Resources
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| NG-641 | EnAd-FAP-BiTE; EnAd-FAP-Tac; NG-641; NG-aFAP | Phase 1 Clinical | Akamis Bio Ltd, University Of Oxford | Squamous Cell Carcinoma of Head and Neck; Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
Customer Reviews